; Telephone 020 7848 0924; Fax 020 7848 0866 ‡ Data used in preparation of this article were obtained from the Alzheimers Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data, but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at http //adni.loni.usc.edu/wp−content/uploads/how to apply/ADNI Acknowledgement List.pdf. 
Introduction
were analyzed in one laboratory and collected using single-parameter ELISA kits (Innogenetics, Ghent, 140 Belgium). CSF amyloid samples were dichotomized using the previously published threshold of 550pg/ml. 
ADNI

142
For ADNI, datasets used to extract CSF measures of amyloid were chosen to maximize sample size. The 143 dataset 'UPENNBIOMK2' was used for ADNI 1 and 'UPENNBIOMK6' for ADNI 2 and ADNI GO. Both 144 datasets contain CSF measurements collected using the xMAP Luminex platform and Innogenetics im-145 munoassay kits. The CSF measures were dichotomized at the previously published threshold (192 pg/ml). we included these estimates as priors using a multivariate normal distribution (see Table 1 ). The PGRS had 174 a non-informative multivariate normal prior with mean 0 and variance 100. We also created models where 175 all variables had the non-informative Normal(0,100) priors for comparison. MCI is used as the reference diagnosis.
APOE status 1 (at least one 4 allele) is used as the reference level. Kruskal Wallis chi-squared was used to test between normal and abnormal groups for continuous demographic variables.
Fishers exact was used to test between normal and abnormal groups for categorical demographic variables. 
